open access

Vol 13, No 3 (2008)
Untitled
Published online: 2008-05-01
Submitted: 2007-10-17
Get Citation

Permanent implants in treatment of prostate cancer

Marek KANIKOWSKI, Janusz SKOWRONEK, Magda KUBASZEWSKA, Adam CHICHEŁ, Piotr MILECKI
DOI: 10.1016/S1507-1367(10)60006-5
·
Rep Pract Oncol Radiother 2008;13(3):150-167.

open access

Vol 13, No 3 (2008)
Untitled
Published online: 2008-05-01
Submitted: 2007-10-17

Abstract

Low-dose rate brachytherapy (LDR – BT) is one of the radiation methods that is known for several years in treatment of localized prostate cancer. The main idea of this method is to implant small radioactive seeds as a source of radiation, directly into the prostate gland. LDR brachytherapy is applied as a monotherapy and also used along with external beam radiation therapy (EBRT) as a boost. In most cases it is used as a sole radical treatment modality, however not as a palliative treatment. The application of permanent seeds implants is a curative treatment alternative in patients with organ-confined cancer, without extracapsular extension of the tumour. Nowadays three kinds of radionuclide (I-125, Pd-103, Cs-131) are in use worldwide. This technique is particular favorite in United States, in Europe however, high-dose rate brachytherapy method (HDR BT) is more popular in early staged prostate cancer treatment (as a boost). HDR-BT monotherapy for early stage prostate cancer is still an investigational treatment. As monotherapy LDR-BT seems to be a reliable choice for early stage prostate cancer, according to low morbidity rate good results and short hospitalization. It is curative alternative of radical prostatectomy or external beam radiation (i.e. 3D CRT, IMRT) with comparable long-term survival and biochemical control and most favorable toxicity. The aim of this publication is to describe methods, indications, complications and selected results of prostate cancer LDR brachytherapy.

Abstract

Low-dose rate brachytherapy (LDR – BT) is one of the radiation methods that is known for several years in treatment of localized prostate cancer. The main idea of this method is to implant small radioactive seeds as a source of radiation, directly into the prostate gland. LDR brachytherapy is applied as a monotherapy and also used along with external beam radiation therapy (EBRT) as a boost. In most cases it is used as a sole radical treatment modality, however not as a palliative treatment. The application of permanent seeds implants is a curative treatment alternative in patients with organ-confined cancer, without extracapsular extension of the tumour. Nowadays three kinds of radionuclide (I-125, Pd-103, Cs-131) are in use worldwide. This technique is particular favorite in United States, in Europe however, high-dose rate brachytherapy method (HDR BT) is more popular in early staged prostate cancer treatment (as a boost). HDR-BT monotherapy for early stage prostate cancer is still an investigational treatment. As monotherapy LDR-BT seems to be a reliable choice for early stage prostate cancer, according to low morbidity rate good results and short hospitalization. It is curative alternative of radical prostatectomy or external beam radiation (i.e. 3D CRT, IMRT) with comparable long-term survival and biochemical control and most favorable toxicity. The aim of this publication is to describe methods, indications, complications and selected results of prostate cancer LDR brachytherapy.

Get Citation

Keywords

prostate cancer; LDR brachytherapy; radioactive isotope; permanent implants; seeds

About this article
Title

Permanent implants in treatment of prostate cancer

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 13, No 3 (2008)

Pages

150-167

Published online

2008-05-01

DOI

10.1016/S1507-1367(10)60006-5

Bibliographic record

Rep Pract Oncol Radiother 2008;13(3):150-167.

Keywords

prostate cancer
LDR brachytherapy
radioactive isotope
permanent implants
seeds

Authors

Marek KANIKOWSKI
Janusz SKOWRONEK
Magda KUBASZEWSKA
Adam CHICHEŁ
Piotr MILECKI

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl